CFSP Practice Test

Certifications > CFSP > Practice Test

CFSP Practice Test (V1)

Dive into practice questions

Question 1

What is the primary function of a Pharmacy & Therapeutics (P&T) Committee within a health system or managed care organization?

  1. To manage the procurement and inventory of all pharmaceuticals.
  2. To develop and maintain the medication formulary by evaluating the clinical efficacy, safety, and value of drugs.
  3. To provide direct patient counseling on high-cost specialty medications.
  4. To discipline prescribers who do not adhere to the formulary.

Question 2

A new biologic for rheumatoid arthritis has an Incremental Cost-Effectiveness Ratio (ICER) of $175,000 per Quality-Adjusted Life Year (QALY) gained compared to the current standard of care. What does this value represent?

  1. The new biologic costs $175,000 more per year than the standard of care.
  2. It costs an additional $175,000 to achieve one QALY with the new biologic compared to the alternative.
  3. The total budget impact of adopting the new biologic will be $175,000.
  4. The new biologic is not cost-effective and should be rejected for formulary addition.

Question 3

A health plan is implementing a four-tier formulary. Which tier would a high-cost, non-preferred brand-name drug most likely be placed in to manage costs and utilization?

  1. Tier 1
  2. Tier 2
  3. Tier 3
  4. Tier 4

Question 4

The primary goal of conducting a Medication Use Evaluation (MUE) for a newly added formulary agent is to:

  1. Determine if the drug is being used in a safe, effective, and appropriate manner according to established criteria.
  2. Calculate the total revenue generated by the dispensing of the new drug.
  3. Identify physicians who are the highest prescribers of the medication.
  4. Negotiate a lower acquisition cost with the drug manufacturer.

Answer Key

  • Question 1: B. To develop and maintain the medication formulary by evaluating the clinical efficacy, safety, and value of drugs. (The P&T committee’s core responsibility is evidence-based assessment of medications to guide formulary decisions, ensuring patient access to safe, effective, and affordable treatments.)
  • Question 2: B. It costs an additional $175,000 to achieve one QALY with the new biologic compared to the alternative. (ICER is a critical pharmacoeconomic metric that quantifies the additional cost for each additional unit of health benefit, providing a standardized way to assess value.)
  • Question 3: D. Tier 4 (Formulary tiers are structured with increasing patient cost-sharing. Tier 1 is typically for preferred generics, while the highest tiers (often Tier 4 or 5) are reserved for non-preferred or specialty drugs to incentivize the use of more cost-effective alternatives.)
  • Question 4: A. Determine if the drug is being used in a safe, effective, and appropriate manner according to established criteria. (MUEs are a quality improvement tool used to analyze the actual use of a medication in a patient population against predefined, evidence-based criteria, ensuring it aligns with the expectations set during the formulary review process.)